Advanced Medical Solutions Group (LSE:AMS) 3-Year EBITDA Growth Rate : 23.00% (As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Advanced Medical Solutions Group 3-Year EBITDA Growth Rate?

Advanced Medical Solutions Group's EBITDA per Share for the six months ended in Jun. 2024 was £0.05.

During the past 12 months, Advanced Medical Solutions Group's average EBITDA Per Share Growth Rate was -26.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 23.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 2.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Advanced Medical Solutions Group was 166.80% per year. The lowest was -22.10% per year. And the median was 20.20% per year.

Competitive Comparison of Advanced Medical Solutions Group's 3-Year EBITDA Growth Rate

For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Medical Solutions Group's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Advanced Medical Solutions Group's 3-Year EBITDA Growth Rate falls into.

Advanced Medical Solutions Group 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Advanced Medical Solutions Group (LSE:AMS) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Advanced Medical Solutions Group 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Advanced Medical Solutions Group's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Medical Solutions Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Medical Solutions Group PLC (LSE:AMS) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AMS.GB:UK AQA:Germany

Address

Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT

Website

https://www.admedsol.com

UK-based Advanced Medical Solutions was founded in 1991 to design, develop, and manufacture advanced wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The firm derives approximately 60% of total revenue from branded products, with nonbranded contributing 40%.